The Challenge of Metastatic Melanoma Metastatic melanoma of the skin has an aggressive course with high morbidity and mortality. While early-stage, non-metastatic primary melanoma has a favorable outcome with surgical excision, metastatic disease remains difficult to treat. From 1993 to 2012, the global incidence per 100,000 persons nearly doubled, and in 2012, there were 232,000 new cases with 55,000 deaths worldwide.
The ceRNA Hypothesis Competing endogenous RNA (ceRNA) networks describe how lncRNAs can act as 'sponges' for microRNAs (miRNAs), thereby releasing target mRNAs from miRNA-mediated suppression. This interaction creates a complex regulatory layer controlling gene expression without altering the DNA sequence. Understanding the ceRNA network in melanoma could reveal new mechanisms driving metastasis.
Study Goal This study used publicly available bioinformatics data from The Cancer Genome Atlas (TCGA) to perform an integrative analysis of lncRNA, miRNA, and mRNA expression in metastatic versus primary melanoma. The goal was to construct a ceRNA regulatory network and identify RNA species whose expression levels correlate with patient survival time.
Dataset TCGA level-3 counts data were downloaded for 471 cases with transcriptome sequencing (lncRNA and mRNA) and 452 cases with miRNA sequencing. Among the 471 samples, 103 were primary solid tumors and 368 were metastatic melanoma. These two groups were compared to identify differentially expressed RNA species.
Differential Expression Analysis The edgeR package in R version 3.4.4 was used to identify differentially expressed genes. The cutoff for mRNA and lncRNA was log fold-change greater than or equal to 2 and FDR less than 0.05; for miRNA, the cutoff was log fold-change greater than or equal to 1 and FDR less than 0.05. GO and KEGG pathway enrichment analyses were performed using the clusterProfiler package.
Network Construction miRNA-mRNA target interactions were predicted using miRDB, miRTarBase, and TargetScan, and only interactions supported by all three databases were retained. lncRNA-miRNA interactions were predicted using the miRcode database. The final ceRNA network was visualized using Cytoscape version 3.6.0, and survival analysis was performed using the Cox regression model in R.
mRNA Changes A total of 856 differentially expressed mRNAs (DEmRNAs) were identified: 426 upregulated and 430 downregulated. Top upregulated genes in metastatic melanoma included C7, CR1, LIFR, SFTPB, TNFSF11, and ADAMTSL3. Top downregulated genes included CNFN, TGM1, S100A9, ASPRV1, CYSRT1, and S100A8.
miRNA and lncRNA Changes In the miRNA dataset, 47 miRNAs were upregulated (including hsa-mir-675, -153-2, -326, and -29c) and 20 were downregulated (including hsa-mir-944, -122, -200c, -203, and -200a). For lncRNAs, 184 were upregulated (including LINC01235, LINC00824, and CHRM3-AS2) and 66 were downregulated (including FAM41C, LINC01214, and NCF4-AS1).
Pathway Enrichment GO analysis of the 856 DEmRNAs identified 74 enriched biological process terms and 19 cellular component terms. Top GO terms included keratinocyte differentiation, keratinization, skin development, and cornification - processes relevant to the skin epithelial environment in which melanoma develops. KEGG analysis identified 13 pathways including retinol metabolism, steroid hormone biosynthesis, arachidonic acid metabolism, and neuroactive ligand-receptor interaction.
Network Scale Of the hundreds of differentially expressed RNAs, 25 miRNAs, 18 lncRNAs, and 18 mRNAs met criteria to participate in the ceRNA network based on predicted binding interactions. The network contained 77 pairs of interactive relationships, including 16 miRNA-mRNA pairs and 1 miRNA-lncRNA pair.
Key Interactions Only two mRNAs, TMEM100 and LUZP2, were found to participate in miRNA-lncRNA interaction within the network - suggesting these are the key regulatory hubs where lncRNA sponging activity influences mRNA expression levels. The network diagram visualized the directionality of regulatory relationships between the three RNA classes.
Network Significance The ceRNA model provides a framework for understanding how noncoding RNAs coordinate gene expression during melanoma progression. By identifying which lncRNAs regulate which miRNAs, and which miRNAs suppress which mRNAs, the network map points to specific molecular pathways that could be targeted therapeutically to disrupt the metastatic program.
Survival-Correlated lncRNAs Six lncRNAs showed significant associations with overall survival: AC068594.1, C7orf71, FAM41C, GPC5-AS1, MUC19, and LINC00402. High expression of AC068594.1 and C7orf71 (both downregulated in metastatic melanoma) correlated with better survival, while lower FAM41C expression correlated with improved outcomes. The survival directions of GPC5-AS1, MUC19, and LINC00402 were also significant. None of these lncRNAs had been previously reported in melanoma.
Survival-Correlated miRNAs Five upregulated miRNAs correlated with better patient survival: miRNA-29c, miRNA-100, miR-142-3p, miR-150, and miR-516a-2. All five were upregulated in metastatic melanoma yet associated with longer survival, suggesting a complex or context-dependent role. Literature supports miR-150 as an inhibitor of melanoma cell proliferation through MYB suppression, and miR-100 and miR-142-3p as inhibitors in other cancers.
Survival-Correlated mRNAs Seven differentially expressed mRNAs showed survival associations: CCR9, CNR2, DIRAS2, ESRP2, FAM83C, USH1G, and KCNT2. CCR9, a chemokine receptor involved in intestinal metastasis of melanoma, showed high expression with better survival, possibly reflecting complex immune responses. CNR2, a cannabinoid receptor, may suppress tumor migration by anchoring cells via heterodimer formation with CXCR4. DIRAS2 appears to function as a tumor suppressor.
Therapeutic Targeting Potential The identified survival-correlated genes represent potential therapeutic targets. CCR9 inhibitors have been studied for anti-metastatic applications, and CNR2 agonists could theoretically suppress tumor migration by promoting non-functional CXCR4-CNR2 heterodimers at the cell surface. The ceRNA network provides a roadmap for disrupting the regulatory interactions that support metastatic progression.
Biomarker Discovery The six identified lncRNAs - all previously unreported in melanoma - represent novel candidate biomarkers for patient stratification. Tissue expression profiling of these lncRNAs could supplement current staging systems to identify which primary melanoma patients are at highest risk of metastasis and may require closer surveillance or adjuvant therapy.
Advantages of Bioinformatics Approach Using a large, publicly available dataset from TCGA enabled analysis of hundreds of cases - a scale difficult to achieve in any single institution. The integrative analysis across three RNA types simultaneously revealed regulatory relationships that single-gene studies would miss. This approach represents a model for hypothesis generation that can guide targeted experimental validation studies.
Bioinformatics Limitations The study relied entirely on publicly available transcriptomic data without experimental validation. The predicted ceRNA interactions were based on database-derived binding predictions, not experimentally confirmed binding events. The edgeR analysis compared primary versus metastatic melanoma but could not establish whether the observed RNA expression changes are causes or consequences of metastasis.
Clinical Context Gaps The TCGA dataset lacks detailed clinical information on treatment history, tumor microenvironment composition, and mutational landscape that could confound survival associations. Several of the identified survival-correlated RNAs have contradictory expected effects - for example, finding upregulated miRNAs associated with better survival despite their pro-metastatic classification suggests complex feedback mechanisms that require further study.
Experimental Validation Required The ceRNA network and survival associations need validation using in vitro cell line experiments and in vivo animal models. The functional roles of the six novel lncRNAs in melanoma metastasis are entirely unexplored. Future studies should use reporter assays to confirm miRNA sponging activity, and CRISPR-based knockouts to assess the contribution of each identified gene to metastatic behavior.